

Special Issue

Hepatitis C Virus: From Discovery to Nobel Prize

Message from the Guest Editor

The aim of this Special Issue of *Viruses* aims to present up-to-date reviews of different aspects of chronic hepatitis C, after the discovery of hepatitis A virus, hepatitis B virus, hepatitis delta virus, and hepatitis E virus. Their epidemiology, as well as their pathogenesis, have been studied in great detail. The cause of the non-A and non-B post-transfusion hepatitis, however, remained an enigma until the hepatitis C virus was discovered in 1989 by M. Houghton and collaborators, followed by the rapid development of HCV-specific serological and molecular diagnostic assay systems, including HCV genotyping. Our ability to effectively treat chronic viral hepatitis C has resulted in better control of this infection. It is now possible to prevent hepatitis B but not hepatitis C and to cure hepatitis C, with the perspective to meet the World Health Organization goal of elimination of HCV infection by 2030. Unfortunately, there is no vaccine available to date.

Guest Editor

Prof. Dr. Hubert E. Blum

Department of Medicine, University Medical Center Freiburg, Freiburg, Germany

Deadline for manuscript submissions

closed (28 February 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/113073

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).